Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

NCT05084950 | Unknown

• 1 other identifier: PRO_CSM_02_2021
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.

Conditions

SARS-CoV-2; COVID-19; Vaccines; Antibody

Outcome Measures

Primary Outcomes (1)

• Covid-19 Neutralizing Antibodies Measurment

  Inform any individual who has been infected with or vaccinated against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have about their level of immune protection, through a bi-annual follow-up

  24-month period

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a single-centre prospective observational study in the general population of the Principality of Monaco, attending the community public health center of Monaco, for Covid testing and/or vaccination.

You may qualify if:

• Participant must live in the Principality of Monaco
• Deliver a written consent to participate to the study
• And/Or Have been infected with SARS-CoV-2
• And/Or Have been, or are about to be, vaccinated against SARS-CoV-2

You may not qualify if:

• \- None of the above

Sponsors & Collaborators

• Centre Scientifique de Monaco: lead
• Department of Health Affairs, Monaco: collaborator

Study Sites (1)

Centre National de Depistage - Espace Leo Ferre

Monaco, 98000, Monaco

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Eric VOIGLIO, MD, PhD

CONTACT

+37798984850; evoiglio@gouv.mc

Thomas ALTHAUS, MD, PhD

CONTACT

+37798984850; talthaus@gouv.mc

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 19, 2021
• First Posted: October 20, 2021
• Study Start: July 1, 2021
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: October 20, 2021

Record last verified: 2021-10

Locations

MO (1)